115 related articles for article (PubMed ID: 15147078)
1. [Tolerability of riluzole: a review of the literature].
Siniscalchi A
Clin Ter; 2004 Jan; 155(1):25-8. PubMed ID: 15147078
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers.
Le Liboux A; Cachia JP; Kirkesseli S; Gautier JY; Guimart C; Montay G; Peeters PA; Groen E; Jonkman JH; Wemer J
J Clin Pharmacol; 1999 May; 39(5):480-6. PubMed ID: 10234595
[TBL] [Abstract][Full Text] [Related]
3. [Tolerance of riluzole in a phase IIIb clinical trial].
Lacomblez L; Dib M; Doppler V; Faudet A; Robin V; Salachas F; Bensimon G; Meininger V
Therapie; 2002; 57(1):65-71. PubMed ID: 12090150
[TBL] [Abstract][Full Text] [Related]
4. [Adverse efects of riluzole (Rilutek) in the treatment of amyotrophic lateral sclerosis].
Roch-Torreilles I; Camu W; Hillaire-Buys D
Therapie; 2000; 55(2):303-12. PubMed ID: 10967703
[TBL] [Abstract][Full Text] [Related]
5. [What are the etiological medical therapies in amyotrophic lateral sclerosis?].
Dib M
Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S215-4S219. PubMed ID: 17128114
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 trial of riluzole in spinal muscular atrophy.
Russman BS; Iannaccone ST; Samaha FJ
Arch Neurol; 2003 Nov; 60(11):1601-3. PubMed ID: 14623733
[TBL] [Abstract][Full Text] [Related]
7. Effect of riluzole (Rilutek) treatment on plasma amino acid percentages in amyotrophic lateral sclerosis patients.
Iłzecka J; Stelmasiak Z; Solski J; Wawrzycki S; Szpetnar M
Neurol Sci; 2003 Nov; 24(4):290-2. PubMed ID: 14658053
[TBL] [Abstract][Full Text] [Related]
8. What has changed with riluzole?
Meininger V; Lacomblez L; Salachas F
J Neurol; 2000 Dec; 247():19-22. PubMed ID: 11200701
[TBL] [Abstract][Full Text] [Related]
9. Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment.
Andreadou E; Kapaki E; Kokotis P; Paraskevas GP; Katsaros N; Libitaki G; Zis V; Sfagos C; Vassilopoulos D
Clin Neurol Neurosurg; 2008 Mar; 110(3):222-6. PubMed ID: 18055102
[TBL] [Abstract][Full Text] [Related]
10. A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosis.
Gordon PH
Muscle Nerve; 2009 Jun; 39(6):858-60. PubMed ID: 19382169
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis.
Bruno R; Vivier N; Montay G; Le Liboux A; Powe LK; Delumeau JC; Rhodes GR
Clin Pharmacol Ther; 1997 Nov; 62(5):518-26. PubMed ID: 9390108
[TBL] [Abstract][Full Text] [Related]
12. Minocycline in amyotrophic lateral sclerosis: a pilot study.
Pontieri FE; Ricci A; Pellicano C; Benincasa D; Buttarelli FR
Neurol Sci; 2005 Oct; 26(4):285-7. PubMed ID: 16193258
[TBL] [Abstract][Full Text] [Related]
13. An association study of riluzole serum concentration and survival and disease progression in patients with ALS.
Groeneveld GJ; van Kan HJ; Lie-A-Huen L; Guchelaar HJ; van den Berg LH
Clin Pharmacol Ther; 2008 May; 83(5):718-22. PubMed ID: 17898704
[TBL] [Abstract][Full Text] [Related]
14. Riluzole for the treatment of amyotrophic lateral sclerosis.
Saitoh Y; Takahashi Y
Neurodegener Dis Manag; 2020 Dec; 10(6):343-355. PubMed ID: 32847483
[TBL] [Abstract][Full Text] [Related]
15. The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis.
Bensimon G; Doble A
Expert Opin Drug Saf; 2004 Nov; 3(6):525-34. PubMed ID: 15500412
[TBL] [Abstract][Full Text] [Related]
16. [Glutamate antagonist].
Shindo M
No To Shinkei; 1998 Jul; 50(7):597-605. PubMed ID: 9739517
[No Abstract] [Full Text] [Related]
17. Can we eliminate placebo in ALS clinical Trials?
Simmons Z
Muscle Nerve; 2009 Jun; 39(6):861-5. PubMed ID: 19382170
[TBL] [Abstract][Full Text] [Related]
18. Riluzole: a new agent for amyotrophic lateral sclerosis.
Wagner ML; Landis BE
Ann Pharmacother; 1997 Jun; 31(6):738-44. PubMed ID: 9184716
[TBL] [Abstract][Full Text] [Related]
19. Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.
Bryson HM; Fulton B; Benfield P
Drugs; 1996 Oct; 52(4):549-63. PubMed ID: 8891467
[TBL] [Abstract][Full Text] [Related]
20. Riluzole for amyotrophic lateral sclerosis.
Med Lett Drugs Ther; 1995 Dec; 37(963):113-4. PubMed ID: 7500908
[No Abstract] [Full Text] [Related]
[Next] [New Search]
